专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006104812A2 BIOMARKERS FOR PHARMACOGENETIC DIAGNOSIS OF TYPE 2 DIABETES 审中-公开
标题翻译：用于2型糖尿病药物诊断的生物标志物
公开(公告)号：WO2006104812A2
公开(公告)日：2006-10-05
申请号：PCT/US2006/010464
申请日：2006-03-22
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , CHEN, Hong , HUGHES, Thomas, Edward
发明人： CHEN, Hong , HUGHES, Thomas, Edward
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： Significant associations between SNPs in TCF2, ACADSB, CPT1A, ESRRA, PPARD, PPARGC1A and SCD1 and diabetes were observed. In addition, significant association was also observed between haplotypes in ESRRA, PPARD, and ACACB and diabetes.
摘要翻译：观察到TCF2，ACADSB，CPT1A，ESRRA，PPARD，PPARGC1A和SCD1和糖尿病的SNP之间的显着关联。此外，在ESRRA，PPARD和ACACB和糖尿病的单倍型之间也观察到显着的关联。

2. 发明申请

WO2007035665A1 USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS 审中-公开
标题翻译：使用DPP-IV抑制剂减少高血压事件
公开(公告)号：WO2007035665A1
公开(公告)日：2007-03-29
申请号：PCT/US2006/036338
申请日：2006-09-18
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , BALKAN, Börk , HOLMES, David, Grenville , HUGHES, Thomas, Edward , VILLHAUER, Edwin, Bernard
发明人： BALKAN, Börk , HOLMES, David, Grenville , HUGHES, Thomas, Edward , VILLHAUER, Edwin, Bernard
IPC分类号： A61K45/06
CPC分类号： A61K45/06 , A61K31/155 , A61K31/64 , A61K38/28 , A61K2300/00
摘要： The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及一种减少低血糖事件的方法，特别是由胰岛素治疗引起的切断的低血糖事件，其中患者用二肽基肽酶IV抑制剂（DPP-IV抑制剂）或其药学上可接受的盐治疗。

3. 发明申请

WO2007041368A2 COMBINATION OF ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的组合
公开(公告)号：WO2007041368A2
公开(公告)日：2007-04-12
申请号：PCT/US2006/038203
申请日：2006-09-28
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , ALLISON, Malcolm , BURKEY, Bryan , HUGHES, Thomas, Edward , KEMP, Daniel, Matthew
发明人： ALLISON, Malcolm , BURKEY, Bryan , HUGHES, Thomas, Edward , KEMP, Daniel, Matthew
IPC分类号： A61K31/40 , A61P3/10 , A61P17/06 , A61P37/06
CPC分类号： A61K45/06 , A61K31/40 , A61K2300/00
摘要： The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and comprising at least one immunosuppressive or immunomodulator agent, or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use of such a combination for the prevention, delay of progression or treatment of diseases and disorders that may be inhibited by DPP IV inhibition, for the prevention, delay of progression or treatment of autoimmune diseases, and the disorders associated therewith, or for the prevention, delay of progression or treatment of graft rejection.
摘要翻译：本发明涉及分别包含DPP IV抑制剂或其药学上可接受的盐并且包含至少一种免疫抑制剂或免疫调节剂或其药学上可接受的盐的组合制剂或药物组合物的组合。本发明还涉及这种组合用于预防，延缓进展或治疗DPP IV抑制可能被抑制的疾病和病症，用于预防，延缓进展或治疗自身免疫性疾病以及该疾病的用途或用于预防，延缓进展或治疗移植排斥反应。

4. 发明申请

WO2005079795A2 USE OF ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的使用
公开(公告)号：WO2005079795A2
公开(公告)日：2005-09-01
申请号：PCT/EP2005/001729
申请日：2005-02-18
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , HUGHES, Thomas, Edward
发明人： HUGHES, Thomas, Edward
IPC分类号： A61K31/4439
CPC分类号： A61K31/00 , A61K31/40 , A61K31/4196 , A61K31/4439 , A61K31/472
摘要： The invention relates to the use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment of neurodegenerative disorders, cognitive disorders and for improving memory (both short term and long term) and learning ability.
摘要翻译：本发明涉及二肽基肽酶IV抑制剂（DPP-IV抑制剂）或其药学上可接受的盐在预防，延缓进展或治疗神经变性疾病，认知障碍和改善记忆（短期和长期期限）和学习能力。

5. 发明申请

WO2005049022A2 USE OF ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的使用
公开(公告)号：WO2005049022A2
公开(公告)日：2005-06-02
申请号：PCT/EP2004/012990
申请日：2004-11-16
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , PRATLEY, Richard , FOLEY, James, E. , HUGHES, Thomas, Edward
发明人： PRATLEY, Richard , FOLEY, James, E. , HUGHES, Thomas, Edward
IPC分类号： A61K31/4439
CPC分类号： A61K31/403 , A61K31/00 , A61K31/40 , A61K31/4025 , A61K31/426 , A61K31/4439 , A61K31/472 , A61K31/4985
摘要： Use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor), preferably (S)-1-[(3-hydroxy-1-adamantyl)amino] acetyl-2-cyano-pyrrolidine or a pharmaceutically acceptable salt thereof for the treatment of cardiovascular diseases or damages, renal diseases or damages, Heart Failure, or Heart Failure associated diseases.
摘要翻译：二肽基肽酶IV抑制剂（DPP-IV抑制剂），优选（S）-1 - [（3-羟基-1-金刚烷基）氨基]乙酰基-2-氰基吡咯烷或其药学上可接受的盐在治疗心血管疾病或损伤，肾脏疾病或损伤，心力衰竭或心力衰竭相关疾病。

6. 发明申请

WO2006041976A1 COMBINATION OF ORGANIC COMPOUNDS 审中-公开
标题翻译：有机化合物的组合
公开(公告)号：WO2006041976A1
公开(公告)日：2006-04-20
申请号：PCT/US2005/035917
申请日：2005-10-06
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BURKEY, Bryan , HUGHES, Thomas, Edward
发明人： BURKEY, Bryan , HUGHES, Thomas, Edward
IPC分类号： A61K31/506 , A61K31/401 , A61P3/10
CPC分类号： A61K31/401 , A61K31/506 , A61K2300/00
摘要： The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising; i) DPP IV inhibitor or a pharmaceutically acceptable salt thereof, and ii) at least one PDGF receptor tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use of such a combination for the prevention, delay of progression or treatment of a disease or condition selected from insulin resistance, impaired glucose metabolism (IGT), conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, diabetes particularly type 1 or type 2 diabetes mellitus, obesity, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, erectile dysfunction, premenstrual syndrome, coronary heart disease, hypertension, angina pectoris, myocardial infarction, stroke, vascular restenosis, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance, and vascular events, cardiovascular morbidity or mortality associated with diabetes (e.g. type I or II) or IGT.
摘要翻译：本发明分别涉及组合，例如组合制剂或药物组合物，其包含： i）DPP IV抑制剂或其药学上可接受的盐，和ii）至少一种PDGF受体酪氨酸激酶抑制剂或其药学上可接受的盐。本发明还涉及这种组合用于预防，延缓进展或治疗选自胰岛素抵抗，葡萄糖代谢异常（IGT），葡萄糖耐量降低的病症，空腹血浆葡萄糖受损状况，糖尿病，特别是1型或2型糖尿病，肥胖症，糖尿病性视网膜病变，黄斑变性，白内障，糖尿病性肾病，肾小球硬化，糖尿病性神经病，勃起功能障碍，经前期综合征，冠心病，高血压，心绞痛，心肌梗塞，中风，血管再狭窄，皮肤和结缔组织疾病，足部溃疡和溃疡性结肠炎，血管内皮功能障碍和血管依从性受损，以及与糖尿病（例如I型或II型）或IGT相关的血管事件，心血管发病率或死亡率。

7. 发明申请

WO2003101448A1 THE USE OF SUBSTITUTED CYANOPYRROLIDINES AND COMBINATION PREPARATIONS CONTAINING THEM FOR TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES 审中-公开
标题翻译：使用替代的CYANOPRROLIDINES和组合制剂，用于治疗高脂血症和相关疾病
公开(公告)号：WO2003101448A1
公开(公告)日：2003-12-11
申请号：PCT/EP2003/005762
申请日：2003-06-02
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , HOLMES, David, Grenville , HUGHES, Thomas, Edward
发明人： HOLMES, David, Grenville , HUGHES, Thomas, Edward
IPC分类号： A61K31/40
CPC分类号： A61K31/401 , A61K31/40 , A61K45/06 , A61K2300/00
摘要： Disclosed are methods and compositions for the treatment of hyperlipidemia and conditions associated therewith, such as CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g. necrosis and apoptosis), dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a compound of formula (I), wherein R is substituted adamantyl; and N is 0 to 3; in free form or in acid addition salt form, and a pharmaceutically acceptable carrier.
摘要翻译：公开了用于治疗高脂血症和与之相关的病症的方法和组合物，例如CHD，缺血性卒中，血管成形术后的再狭窄，外周血管疾病，间歇性跛行，心肌梗死（例如坏死和凋亡），血脂异常和餐后脂肪血症。所述方法包括施用治疗有效量的式（I）化合物，其中R是取代的金刚烷基; N为0〜3; 游离形式或酸加成盐形式，和药学上可接受的载体。

8. 发明申请

WO2003080070A3 COMBINATION COMPRISING AN HMG-COA REDUCTASE INHIBITTOR AND AN INSULIN SECRETOR ENHANCER OR AN INSULIN SENSITIZER 审中-公开
公开(公告)号：WO2003080070A3
公开(公告)日：2003-10-02
申请号：PCT/EP2003/002978
申请日：2003-03-21
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , DAMON, Robert, Edson , HUGHES, Thomas, Edward , BURKEY, Bryan
发明人： DAMON, Robert, Edson , HUGHES, Thomas, Edward , BURKEY, Bryan
IPC分类号： A61K31/64
摘要： The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.

9. 发明申请

WO2003099279A1 COMBINATION OF A DPP IV INHIBITOR AND A CARDIOVASCULAR COMPOUND 审中-公开
标题翻译： DPP IV抑制剂和心血管化合物的组合
公开(公告)号：WO2003099279A1
公开(公告)日：2003-12-04
申请号：PCT/EP2003/005639
申请日：2003-05-28
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , HOLMES, David, Grenville , SHETTY, Suraj, Shivappa , HUGHES, Thomas, Edward
发明人： HOLMES, David, Grenville , SHETTY, Suraj, Shivappa , HUGHES, Thomas, Edward
IPC分类号： A61K31/454
CPC分类号： A61K31/454 , A61K31/16 , A61K31/40 , A61K31/41
摘要： The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and a cardiovascular compound (being different from a statin) or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the use of such a combination for the prevention, delay of progression or treatment of diseases and disorders selected from the group consisting of hypertension, congestive heart failure, left ventricular hypertrophy, peripheral arterial disease, diabetes, especially type 2 diabetes mellitus, diabetic retinophathy, macular degeneration, cataract, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, thrombosis, atherosclerosis, myocardial infarction, transient ischemic attacks, stroke, vascular restenosis, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertryglyceridemia, insulin resistance, impaired glucose metabolism, conditions of impaired glucose tolerance, conditions of impaired fasting plasma glucose, obesity, erectile dysfunction, skin and connective tissue disorders, foot ulcerations and ulcerative colitis, endothelial dysfunction and impaired vascular compliance.
摘要翻译：本发明涉及分别包含DPP IV抑制剂或其药学上可接受的盐和心血管化合物（不同于他汀类）或其药学上可接受的盐的组合制剂或药物组合物的组合。本发明还涉及这种组合用于预防，延缓进展或治疗选自高血压，充血性心力衰竭，左心室肥大，外周动脉疾病，糖尿病，特别是2型糖尿病，糖尿病性视网膜病变，黄斑变性，白内障，糖尿病肾病，肾小球硬化，慢性肾功能衰竭，糖尿病性神经病，X综合征，经前期综合征，冠心病，心绞痛，血栓形成，动脉粥样硬化，心肌梗死，短暂性脑缺血发作，中风，血管再狭窄，高血糖症，高胰岛素血症，高脂血症，高甘油三酯血症，胰岛素抵抗，糖代谢障碍，葡萄糖耐量降低的病症，空腹血浆葡萄糖受损的病症，肥胖症，勃起功能障碍，皮肤和结缔组织疾病，足部溃疡和溃疡性结肠炎，内皮功能障碍功能受损和血管依从性受损。

10. 发明申请

WO2003038123A2 METHODS TO TREAT DIABETES AND RELATED CONDITIONS BASED ON POLYMORPHISMS IN THE TCF1 GENE 审中-公开
标题翻译：基于TCF1基因多态性治疗糖尿病及相关病症的方法
公开(公告)号：WO2003038123A2
公开(公告)日：2003-05-08
申请号：PCT/EP2002/012113
申请日：2002-10-30
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , HUGHES, Thomas, Edward , LAVEDAN, Christian, Nicolas , POLYMEROPOULOS, Mihael, Hristos
发明人： HUGHES, Thomas, Edward , LAVEDAN, Christian, Nicolas , POLYMEROPOULOS, Mihael, Hristos
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , A61K31/40 , A61K31/4439 , A61K49/0004 , C12Q2600/106 , C12Q2600/156
摘要： This invention relates to the use of the novel association between the 483 A>G single nucleotide polymorphism of the TCF1 gene and the clinical response to glycemic control agents, such as DPPIV inhibitors, in patients with disorders of glycemic control, especially diabetes and impaired glucose metabolism. This invention provides methods to classify patients for treatment and/or for optimization of clinical studies and to treat patients based on this association.
摘要翻译：本发明涉及TCF1基因的483A> G单核苷酸多态性与血糖控制剂如DPPIV抑制剂在血糖控制障碍患者，特别是糖尿病和葡萄糖受损患者中的临床应用之间的新关联的用途代谢。本发明提供了将患者分类用于治疗和/或优化临床研究并基于该关联治疗患者的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式